Dominant negative inhibitor of anthrax toxin

Summary The invention enables prevention and emergency treatment of anthrax. It provides a dominant negative inhibitor (DNI) of an essential infectivity factor of B. anthracis, a potentially lethal pathogen. Animal testing has been performed, and an IND has been filed for human therapeutic use.

The DNI technology is protected by U.S. and international patent applications (see international patent application WO 01/082788). It is available for exclusive- or non-exclusive license in the field of veterinary health.

Reference:

Sellman et al., 2001, "Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax", Science 292(5517): 695-697.

Applications Anthrax therapeutic and vaccine; biodefense/antiterrorism agent. For Further Information Please Contact the Director of Business Development Alex Szidon Email: [email protected] Telephone: (617) 495-3067

Inventor(s): Collier, R. John

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents
« More Medical Patents

Share on      


CrowdSell Your Patent